Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus individualized medical management in HFpEF
NL-OMON46419Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Novartis. Primary endpoints: NT-proBNP at Week 12 and Exercise capacity by six-minute walk test at Week 24. Started Mar 2018; status: active, not recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON46419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46419.